Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02204553
- Locations
- 🇺🇸
Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States
🇺🇸Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, United States
🇺🇸Northern Utah Cancer Associates SC, Ogden, Utah, United States
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 401
- Registration Number
- NCT02202616
- Locations
- 🇨🇦
Novartis Investigative Site, St-Charles-Borromée, Quebec, Canada
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02201290
- Locations
- 🇷🇺
Novartis Investigative Site, Saint Petersburg, Russian Federation
Observation of Treatment Patterns With Lucentis in Approved Indications
- Conditions
- Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5778
- Registration Number
- NCT02194803
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT02190604
- Locations
- 🇬🇧
Novartis Investigative Site, Mid Glamorgan, United Kingdom
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02189174
- Locations
- 🇺🇸
Massachusetts General Hospital SC-9, Boston, Massachusetts, United States
🇺🇸Tennessee Oncology SC, Nashville, Tennessee, United States
🇪🇸Novartis Investigative Site, Barcelona, Catalunya, Spain
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT02187783
- Locations
- 🇺🇸
Northern Indiana Cancer Research Consortium No. Indiana Cancer Res., South Bend, Indiana, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸PCR Oncology, Pismo Beach, California, United States
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02186821
- Locations
- 🇺🇸
Columbus Hematology and Oncology PA Columbus Hem and Onc (2), Columbus, Ohio, United States
🇺🇸MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston, Texas, United States
🇺🇸Swedish Cancer Institute Swedish Cancer Institute, Seattle, Washington, United States
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
- Conditions
- Cushings Disease
- Interventions
- Drug: LCI699 matching placebo
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT02180217
- Locations
- 🇺🇸
University of Colorado Hospital SC - LCI699C2301, Aurora, Colorado, United States
🇺🇸Emory University School of Medicine G2304 - C2301, Atlanta, Georgia, United States
🇺🇸Northwestern University SC - LCI699C2301, Chicago, Illinois, United States
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02177682
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan